A 64-year-old man developed cognitive dysfunction and generalized seizures, followed by episodes of transient speech and gait disturbances lasting several minutes, occurring multiple times per day; the events were not associated with any triggers. Neurologic examination during one of his episodic symptoms (video 1) showed transient ataxic dysarthria. Testing for neural autoantibodies revealed evidence of voltage-gated potassium channel complex antibodies by radioimmunoprecipitation assay; CASPR2-IgG was positive in serum and CSF by cell-based assay. Brain MRI was normal; CSF analysis showed an elevated protein level at 101 mg/dL, but it was otherwise normal. Oncologic evaluation was negative. The cognitive symptoms improved; seizures and episodic ataxia resolved after 12 weeks of treatment with IV methylprednisolone. Episodic ataxia is a manifestation of CASPR2 autoimmunity;1 patients can have normal MRI, and immunotherapy is beneficial.
Author contributions
A.S. Lopez-Chiriboga and S. Pittock contributed to the conception and design of the study; collection, analysis, and interpretation of the data; drafting and critical revision of the manuscript; and generation/collection of the figures. Both authors gave final approval of the manuscript.
Study funding
No targeted funding reported.
Disclosure
A.S. Lopez-Chiriboga reports no disclosures. S. Pittock has a patent pending for GFAP, Septin-5 and MAP1B autoantibodies as biomarkers of neurological autoimmumity; received research support from Grifols, MedImmune, Alexion, AEA, and NIH; had compensation for consulting activities paid to Mayo Clinic from Alexion and MedImmune; and has a financial interest with Mayo Clinic in patents that relate to functional AQP4/NMO-IgG assays and NMO-IgG as a cancer marker. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/NN.
Reference
- 1.Joubert B, Gobert F, Thomas L, et al. Autoimmune episodic ataxia in patients with anti-CASPR2 antibody-associated encephalitis. Neurol Neuroimmunol Neuroinflamm 2017;4:e371. doi: 10.1212/NXI.0000000000000371. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.